<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02720523</url>
  </required_header>
  <id_info>
    <org_study_id>M14-663</org_study_id>
    <nct_id>NCT02720523</nct_id>
  </id_info>
  <brief_title>A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs</brief_title>
  <acronym>SELECTSUNRISE</acronym>
  <official_title>A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Japanese Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind study comparing ABT-494 to placebo in Japanese
      participants with moderately to severely active rheumatoid arthritis who are on a stable dose
      of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and have an
      inadequate response.

      Following marketing approval of upadacitinib for rheumatoid arthritis in Japan, this study
      will become a post-marketing clinical study and include a long-term extension period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consisted of a 35-day screening period; a 12-week randomized, double-blind,
      parallel-group, placebo-controlled treatment period (Period 1); a 248-week blinded long-term
      extension period (Period 2); and a 30-day follow-up period (call or visit).

      Participants who met eligibility criteria were randomized in a 3:3:3:1:1:1 ratio to one of
      six treatment groups:

        -  Group 1: Upadacitinib 7.5 mg QD (Period 1) → upadacitinib 7.5 mg QD (Period 2)

        -  Group 2: Upadacitinib 15 mg QD (Period 1) → upadacitinib 15 mg QD (Period 2)

        -  Group 3: Upadacitinib 30 mg QD (Period 1) → upadacitinib 30 mg QD (Period 2)

        -  Group 4: Placebo (Period 1) → upadacitinib 7.5 mg QD (Period 2)

        -  Group 5: Placebo (Period 1) → upadacitinib 15 mg QD (Period 2)

        -  Group 6: Placebo (Period 1) → upadacitinib 30 mg QD (Period 2)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 22, 2016</start_date>
  <completion_date type="Anticipated">January 14, 2022</completion_date>
  <primary_completion_date type="Actual">August 3, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score 28 (DAS28) (CRP) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.
A negative change from Baseline in the overall score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:
≥ 50% improvement in 68-tender joint count;
≥ 50% improvement in 66-swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
≥ 70% improvement in 68-tender joint count;
≥ 70% improvement in 66-swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).
The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Low disease activity. was defined as a DAS28 score less than or equal to 3.2. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical remission was defined as a DAS28 (CRP) score less than 2.6. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1</measure>
    <time_frame>Baseline and Week 1</time_frame>
    <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The FACIT Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better quality of life. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rheumatoid Arthritis Work Instability Scale (RA-WIS) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>RA-WIS is a simple validated tool to evaluate work instability (the consequence of a mismatch between an individual's functional ability and their work tasks). RA-WIS consists of 23 questions relating to the participant's functioning in their work environment, each answered as Yes or No. The total score is the number of questions answered Yes, and ranges from 0 to 23.
A score &lt; 10 means low risk and no action is needed, scores between 10 and 17 indicate medium risk and appropriate advice and information should be given. If the score is &gt; 17, it means high risk and it could warrant referral.
A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Severity of Morning Stiffness at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Morning stiffness severity was determined by the Patient's Assessment of Severity and Duration of Morning Stiffness questionnaire. Participants rated the severity of morning stiffness on awakening over the past 7 days on a scale from 0 (No morning stiffness) to 10 (Worst possible morning stiffness).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo / Upadacitinib 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants will receive placebo once daily for 12 weeks.
Period 2: Participants will receive Upadacitinib 7.5 mg once daily for 248 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo / Upadacitinib 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants will receive placebo once daily for 12 weeks.
Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo / Upadacitinib 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants will receive placebo once daily for 12 weeks.
Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Upadacitinib 7.5 mg / Upadacitinib 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants will receive upadacitinib 7.5 mg once daily for 12 weeks.
Period 2: Participants will receive upadacitinib 7.5 mg once daily for 248 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Upadacitinib 15 mg / Upadacitinib 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants will receive upadacitinib 15 mg once daily for 12 weeks.
Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Upadacitinib 30 mg / Upadacitinib 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants will receive upadacitinib 30 mg once daily for 12 weeks.
Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Placebo / Upadacitinib 15 mg</arm_group_label>
    <arm_group_label>Placebo / Upadacitinib 30 mg</arm_group_label>
    <arm_group_label>Placebo / Upadacitinib 7.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Placebo / Upadacitinib 15 mg</arm_group_label>
    <arm_group_label>Placebo / Upadacitinib 30 mg</arm_group_label>
    <arm_group_label>Placebo / Upadacitinib 7.5 mg</arm_group_label>
    <arm_group_label>Upadacitinib 15 mg / Upadacitinib 15 mg</arm_group_label>
    <arm_group_label>Upadacitinib 30 mg / Upadacitinib 30 mg</arm_group_label>
    <arm_group_label>Upadacitinib 7.5 mg / Upadacitinib 7.5 mg</arm_group_label>
    <other_name>ABT-494</other_name>
    <other_name>RINVOQ™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of rheumatoid arthritis (RA) for &gt;= 3 months who also fulfill the 2010
             American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR)
             classification criteria for RA.

          -  Subjects have been receiving conventional synthetic disease-modifying anti-rheumatic
             drug (csDMARD) therapy &gt;= 3 months and on a stable dose for &gt;= 4 weeks prior to the
             first dose of study drug.

          -  Subject has &gt;= 6 swollen joints (based on 66 joint counts) and &gt;= 6 tender joints
             (based on 68 joint counts) at Screening and Baseline Visits.

          -  Subjects with prior exposure to at most one biological disease-modifying
             anti-rheumatic drug (bDMARD) may be enrolled (up to 20% of total number of subjects)
             after the required washout period. Specifically, prior to enrollment:

               1. Subjects with limited exposure to bDMARD (&lt; 3 months) OR

               2. Subjects who are responding to bDMARD therapy but had to discontinue due to
                  intolerability (regardless of treatment duration).

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor

          -  Subjects who are considered inadequate responders (lack of efficacy) to bDMARD
             therapy, after minimum 3 months treatment, as determined by the Investigator.

          -  History of any arthritis with onset prior to age 17 years or current diagnosis of
             inflammatory joint disease other than RA (including but not limited to gout, systemic
             lupus erythematosus, psoriatic arthritis, axial spondyloarthritis [SpA] including
             ankylosing spondylitis and non-radiographic axial SpA, reactive arthritis, overlap
             connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia
             [currently with active symptoms]). Current diagnosis of secondary Sjogren's Syndrome
             is permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya University Hospital /ID# 148005</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamanomachi Hospital /ID# 147991</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>810-8539</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital /ID# 148008</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inoue Hospital /ID# 147966</name>
      <address>
        <city>Takasaki</city>
        <state>Gunma</state>
        <zip>3700053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Asahikawa Medical Center /ID# 147994</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <zip>070-8644</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katayama Orthopedic Rheumatology Clinic /ID# 147976</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <zip>078-8243</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital of Hyogo College of Medicine /ID# 147978</name>
      <address>
        <city>Nishinomiya-shi</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Sagamihara National Hospital /ID# 148221</name>
      <address>
        <city>Sagamihara-shi</city>
        <state>Kanagawa</state>
        <zip>252-0315</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Osaka Minami Med Ctr /ID# 147986</name>
      <address>
        <city>Osaka</city>
        <state>Kawachinagano-shi</state>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Orthopaedic Hospital /ID# 147972</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital /ID# 148435</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Keiai Kai Clinic /ID# 147975</name>
      <address>
        <city>Miyazaki-shi</city>
        <state>Miyazaki</state>
        <zip>880-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagaoka Red Cross Hospital /ID# 147974</name>
      <address>
        <city>Nagaoka-shi</city>
        <state>Niigata</state>
        <zip>940-2108</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Rheumatic Center /ID# 148002</name>
      <address>
        <city>Shibata-shi</city>
        <state>Niigata</state>
        <zip>957-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center, Saitama Medical University /ID# 147965</name>
      <address>
        <city>Kawagoe-shi</city>
        <state>Saitama</state>
        <zip>350-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital /ID# 148220</name>
      <address>
        <city>Shimotsuke-shi</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Luke's International Hospital /ID# 147969</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ichinomiya Municipal Hospital /ID# 147992</name>
      <address>
        <city>Ichinomiya-shi</city>
        <state>Tokyo</state>
        <zip>491-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center /ID# 148003</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>1538515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setagaya Rheumatic Clinic /ID# 148009</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>156-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital /ID# 147982</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital /ID# 148007</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Uchida Clinic /ID# 148219</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <zip>130-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokito Clinic Rheumatology and Orthopaedics Surgery /ID# 147980</name>
      <address>
        <city>Shimonoseki-shi</city>
        <state>Yamaguchi</state>
        <zip>752-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Chiba-East-Hospital /ID# 147996</name>
      <address>
        <city>Chiba</city>
        <zip>260-8712</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sugimoto Rheumatology and Internal Medicine Clinic /ID# 147989</name>
      <address>
        <city>Fukui</city>
        <zip>910-0068</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopsital of the University of Occupational and Enviromental Health /ID# 147970</name>
      <address>
        <city>Fukuoka</city>
        <zip>8078556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shono Rheumatism Clinic /ID# 147971</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima Rheumatology Clinic /ID# 147981</name>
      <address>
        <city>Hiroshima-Shi</city>
        <zip>730-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsubara Mayflower Hospital /ID# 147967</name>
      <address>
        <city>Kato</city>
        <zip>673-1462</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Rheumatology Clinic /ID# 147988</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-5515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital /ID# 147979</name>
      <address>
        <city>Kurume</city>
        <zip>830-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa University Hospital /ID# 148001</name>
      <address>
        <city>Kyoto</city>
        <zip>615-8256</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marunouchi Hospital /ID# 147973</name>
      <address>
        <city>Matsumoto</city>
        <zip>390-0841</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yu Family Clinic /ID# 147990</name>
      <address>
        <city>Miyagi</city>
        <zip>981-0112</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP Red Cross Nagoya Daiichi /ID# 147995</name>
      <address>
        <city>Nagoya</city>
        <zip>453-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kondo Clinic for Ortho &amp; Rheum /ID# 147984</name>
      <address>
        <city>Nagoya</city>
        <zip>464-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oribe Clinic of Rheumatology and Internal Medicine /ID# 149308</name>
      <address>
        <city>Oita</city>
        <zip>870-0823</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama City Gen Med Ctr /ID# 148000</name>
      <address>
        <city>Okayama</city>
        <zip>700-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyashita Rheumatology Clinic /ID# 147997</name>
      <address>
        <city>Omura</city>
        <zip>856-0836</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sagawa Akira Rheumatology Clin /ID# 147987</name>
      <address>
        <city>Sapporo</city>
        <zip>060-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo City General Hospital /ID# 147968</name>
      <address>
        <city>Sapporo</city>
        <zip>060-8604</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hikarigaoka Spellman Hospital /ID# 147993</name>
      <address>
        <city>Sendai</city>
        <zip>983-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Honjo Rheumatism Clinic /ID# 147983</name>
      <address>
        <city>Takaoka</city>
        <zip>933-0874</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takikawa Municipal Hospital /ID# 149309</name>
      <address>
        <city>Takikawa</city>
        <zip>073-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital /ID# 147999</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Tokyo Medical Center /ID# 147998</name>
      <address>
        <city>Tokyo</city>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hosp /ID# 147977</name>
      <address>
        <city>Tokyo</city>
        <zip>173-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oki Medical Clinic /ID# 147985</name>
      <address>
        <city>Tomakomai</city>
        <zip>053-0018</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toneyama National Hospital /ID# 148006</name>
      <address>
        <city>Toyonaka</city>
        <zip>560-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related info.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2016</study_first_posted>
  <results_first_submitted>September 13, 2019</results_first_submitted>
  <results_first_submitted_qc>October 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 21, 2019</results_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>ABT-494</keyword>
  <keyword>Japanese</keyword>
  <keyword>Antirheumatic agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02720523/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02720523/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with active rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease-modifying anti-rheumatic drug (csDMARDs) were enrolled at 49 sites in Japan.
The study is currently ongoing, results are reported up to Week 60, as of the data cutoff date of 12 July 2018.</recruitment_details>
      <pre_assignment_details>Participants were randomized to 1 of 3 doses of upadacitinib or placebo in Period 1. Participants who completed week 12 could continue in the study; participants in the upadacitinib groups continued on the same dose of upadacitinib, participants in the placebo group switched to upadacitinib 7.5, 15, or 30 mg per the pre-specified randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Period 1: Placebo</title>
          <description>Participants randomized to receive placebo once daily (QD) for 12 weeks in Period 1.</description>
        </group>
        <group group_id="P2">
          <title>Period 1: Upadacitinib 7.5 mg</title>
          <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="P3">
          <title>Period 1: Upadacitinib 15 mg</title>
          <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="P4">
          <title>Period 1: Upadacitinib 30 mg</title>
          <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="P5">
          <title>Period 2: Upadacitinib 7.5 mg</title>
          <description>Participants received upadacitinib 7.5 mg QD from Week 12 to Week 260 during the long-term extension period.</description>
        </group>
        <group group_id="P6">
          <title>Period 2: Upadacitinib 15 mg</title>
          <description>Participants received upadacitinib 15 mg QD from Week 12 to Week 260 during the long-term extension period.</description>
        </group>
        <group group_id="P7">
          <title>Period 2: Upadacitinib 30 mg</title>
          <description>Participants received upadacitinib 30 mg QD from Week 12 to Week 260 during the long-term extension period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Placebo-controlled Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2: Long-term Extension Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="65">Includes participants originally randomized to placebo and upadacitinib 7.5 mg</participants>
                <participants group_id="P6" count="62">Includes participants originally randomized to placebo and upadacitinib 15 mg</participants>
                <participants group_id="P7" count="60">Includes participants originally randomized to placebo and upadacitinib 30 mg</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="65"/>
                <participants group_id="P6" count="62"/>
                <participants group_id="P7" count="60"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="57"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="B2">
          <title>Upadacitinib 7.5 mg</title>
          <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="B3">
          <title>Upadacitinib 15 mg</title>
          <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="B4">
          <title>Upadacitinib 30 mg</title>
          <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="50"/>
            <count group_id="B5" value="197"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.3" spread="13.04"/>
                    <measurement group_id="B2" value="55.8" spread="11.02"/>
                    <measurement group_id="B3" value="56.0" spread="12.50"/>
                    <measurement group_id="B4" value="54.7" spread="12.22"/>
                    <measurement group_id="B5" value="55.2" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 40 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>45 to &lt; 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of RA Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="4.86"/>
                    <measurement group_id="B2" value="6.7" spread="7.15"/>
                    <measurement group_id="B3" value="5.9" spread="7.20"/>
                    <measurement group_id="B4" value="4.5" spread="4.30"/>
                    <measurement group_id="B5" value="5.5" spread="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Biological Disease-modifying Anti-rheumatic Drug (bDMARD) Use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joint Count</title>
          <description>A total of 68 joints were assessed for the presence or absence of tenderness.</description>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.8" spread="11.42"/>
                    <measurement group_id="B2" value="16.3" spread="8.89"/>
                    <measurement group_id="B3" value="17.8" spread="12.58"/>
                    <measurement group_id="B4" value="16.3" spread="10.79"/>
                    <measurement group_id="B5" value="16.8" spread="10.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Count</title>
          <description>A total of 66 joints were assessed for the presence or absence of swelling.</description>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.9" spread="4.65"/>
                    <measurement group_id="B2" value="11.7" spread="4.89"/>
                    <measurement group_id="B3" value="14.0" spread="7.82"/>
                    <measurement group_id="B4" value="11.7" spread="5.32"/>
                    <measurement group_id="B5" value="12.1" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient's Assessment of Pain</title>
          <description>Participants were asked to indicate the severity of their arthritis pain within the previous week on a visual analog scale (VAS) from 0 to 100 mm. A score of 0 mm indicates &quot;no pain&quot; and a score of 100 mm indicates &quot;worst possible pain.&quot;</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="20.83"/>
                    <measurement group_id="B2" value="57.8" spread="22.62"/>
                    <measurement group_id="B3" value="50.5" spread="25.41"/>
                    <measurement group_id="B4" value="45.5" spread="21.85"/>
                    <measurement group_id="B5" value="52.4" spread="23.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient's Global Assessment of Disease Activity</title>
          <description>The participant was asked to rate their current RA disease activity over the past 24 hours on a 100 mm VAS, where 0 mm indicates very low disease activity and 100 mm indicates very high disease activity.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="21.72"/>
                    <measurement group_id="B2" value="59.0" spread="22.51"/>
                    <measurement group_id="B3" value="49.3" spread="24.89"/>
                    <measurement group_id="B4" value="47.8" spread="22.79"/>
                    <measurement group_id="B5" value="52.4" spread="23.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician's Global Assessment of Disease Activity</title>
          <description>The physician rated the participant's current global RA disease activity (independently from the participant's assessment) on a VAS scale from 0 to 100 mm, where 0 mm indicates very low disease activity and 100 mm indicates very high disease activity.</description>
          <population>Participants with available data</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="48"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="196"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" spread="18.62"/>
                    <measurement group_id="B2" value="55.6" spread="16.65"/>
                    <measurement group_id="B3" value="58.8" spread="20.21"/>
                    <measurement group_id="B4" value="57.6" spread="21.38"/>
                    <measurement group_id="B5" value="57.4" spread="19.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Assessment Questionnaire - Disability Index (HAQ-DI)</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" spread="0.67"/>
                    <measurement group_id="B2" value="0.9" spread="0.67"/>
                    <measurement group_id="B3" value="1.0" spread="0.67"/>
                    <measurement group_id="B4" value="0.9" spread="0.60"/>
                    <measurement group_id="B5" value="0.9" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-sensitivity C-reactive Protein (hsCRP)</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="49"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.9" spread="20.53"/>
                    <measurement group_id="B2" value="13.3" spread="12.80"/>
                    <measurement group_id="B3" value="15.8" spread="18.23"/>
                    <measurement group_id="B4" value="12.4" spread="13.67"/>
                    <measurement group_id="B5" value="14.8" spread="16.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12</title>
        <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 7.5 mg</title>
            <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12</title>
          <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="29.0" upper_limit="56.7"/>
                    <measurement group_id="O2" value="75.5" lower_limit="63.5" upper_limit="87.6"/>
                    <measurement group_id="O3" value="83.7" lower_limit="73.3" upper_limit="94.0"/>
                    <measurement group_id="O4" value="80.0" lower_limit="68.9" upper_limit="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>32.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.3</ci_lower_limit>
            <ci_upper_limit>51.0</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib – Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>40.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.5</ci_lower_limit>
            <ci_upper_limit>58.1</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib – Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>37.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.4</ci_lower_limit>
            <ci_upper_limit>54.9</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib – Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Cochran-Armitage test was conducted for demonstrating a dose response relationship.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Armitage test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score 28 (DAS28) (CRP) at Week 12</title>
        <description>The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; multiple imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 7.5 mg</title>
            <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score 28 (DAS28) (CRP) at Week 12</title>
          <description>The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.</description>
          <population>Full analysis set; multiple imputation was used for missing data.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" lower_limit="-1.158" upper_limit="-0.426"/>
                    <measurement group_id="O2" value="-2.08" lower_limit="-2.430" upper_limit="-1.727"/>
                    <measurement group_id="O3" value="-2.39" lower_limit="-2.735" upper_limit="-2.043"/>
                    <measurement group_id="O4" value="-2.41" lower_limit="-2.776" upper_limit="-2.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model including treatment as the fixed factor, and baseline value and the stratification factor prior bDMARD use as covariates.</method_desc>
            <param_type>Least Squares (LS) Mean Difference</param_type>
            <param_value>-1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.693</ci_lower_limit>
            <ci_upper_limit>-0.880</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model including treatment as the fixed factor, and baseline value and the stratification factor prior bDMARD use as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.005</ci_lower_limit>
            <ci_upper_limit>-1.190</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model including treatment as the fixed factor, and baseline value and the stratification factor prior bDMARD use as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.027</ci_lower_limit>
            <ci_upper_limit>-1.216</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12</title>
        <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.
A negative change from Baseline in the overall score indicates improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available data at baseline; multiple imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 7.5 mg</title>
            <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.
A negative change from Baseline in the overall score indicates improvement.</description>
          <population>Full analysis set participants with available data at baseline; multiple imputation was used for missing data.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" lower_limit="-0.245" upper_limit="0.043"/>
                    <measurement group_id="O2" value="-0.41" lower_limit="-0.545" upper_limit="-0.267"/>
                    <measurement group_id="O3" value="-0.45" lower_limit="-0.583" upper_limit="-0.309"/>
                    <measurement group_id="O4" value="-0.49" lower_limit="-0.636" upper_limit="-0.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model includes treatment as the fixed factor, and the baseline value and stratification factor prior bDMARD use as the covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.465</ci_lower_limit>
            <ci_upper_limit>-0.144</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model includes treatment as the fixed factor, and the baseline value and stratification factor prior bDMARD use as the covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.505</ci_lower_limit>
            <ci_upper_limit>-0.184</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model includes treatment as the fixed factor, and the baseline value and stratification factor prior bDMARD use as the covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.550</ci_lower_limit>
            <ci_upper_limit>-0.229</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12</title>
        <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:
≥ 50% improvement in 68-tender joint count;
≥ 50% improvement in 66-swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 7.5 mg</title>
            <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12</title>
          <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:
≥ 50% improvement in 68-tender joint count;
≥ 50% improvement in 66-swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="6.0" upper_limit="26.7"/>
                    <measurement group_id="O2" value="40.8" lower_limit="27.1" upper_limit="54.6"/>
                    <measurement group_id="O3" value="65.3" lower_limit="52.0" upper_limit="78.6"/>
                    <measurement group_id="O4" value="58.0" lower_limit="44.3" upper_limit="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>24.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.3</ci_lower_limit>
            <ci_upper_limit>41.7</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>49.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.1</ci_lower_limit>
            <ci_upper_limit>65.9</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>41.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.5</ci_lower_limit>
            <ci_upper_limit>58.8</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12</title>
        <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
≥ 70% improvement in 68-tender joint count;
≥ 70% improvement in 66-swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 7.5 mg</title>
            <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12</title>
          <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
≥ 70% improvement in 68-tender joint count;
≥ 70% improvement in 66-swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom ACR data were missing at Week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="20.4" lower_limit="9.1" upper_limit="31.7"/>
                    <measurement group_id="O3" value="34.7" lower_limit="21.4" upper_limit="48.0"/>
                    <measurement group_id="O4" value="28.0" lower_limit="15.6" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>18.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.4</ci_lower_limit>
            <ci_upper_limit>30.3</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>32.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.7</ci_lower_limit>
            <ci_upper_limit>46.6</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>26.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.9</ci_lower_limit>
            <ci_upper_limit>39.0</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12</title>
        <description>The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).
The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 7.5 mg</title>
            <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12</title>
          <description>The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).
The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.</description>
          <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" lower_limit="1.03" upper_limit="4.72"/>
                    <measurement group_id="O2" value="7.21" lower_limit="5.43" upper_limit="8.99"/>
                    <measurement group_id="O3" value="6.38" lower_limit="4.60" upper_limit="8.15"/>
                    <measurement group_id="O4" value="8.81" lower_limit="6.93" upper_limit="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.10</ci_lower_limit>
            <ci_upper_limit>6.57</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>5.75</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.64</ci_lower_limit>
            <ci_upper_limit>8.22</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12</title>
        <description>Low disease activity. was defined as a DAS28 score less than or equal to 3.2. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom DAS28 data were missing at Week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 7.5 mg</title>
            <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12</title>
          <description>Low disease activity. was defined as a DAS28 score less than or equal to 3.2. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom DAS28 data were missing at Week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="7.5" upper_limit="29.2"/>
                    <measurement group_id="O2" value="53.1" lower_limit="39.1" upper_limit="67.0"/>
                    <measurement group_id="O3" value="69.4" lower_limit="56.5" upper_limit="82.3"/>
                    <measurement group_id="O4" value="72.0" lower_limit="59.6" upper_limit="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>34.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.0</ci_lower_limit>
            <ci_upper_limit>52.4</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>51.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34.2</ci_lower_limit>
            <ci_upper_limit>67.9</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>53.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.1</ci_lower_limit>
            <ci_upper_limit>70.1</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12</title>
        <description>Clinical remission was defined as a DAS28 (CRP) score less than 2.6. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom DAS28 data were missing at Week 12 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 7.5 mg</title>
            <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12</title>
          <description>Clinical remission was defined as a DAS28 (CRP) score less than 2.6. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 12 or for whom DAS28 data were missing at Week 12 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O2" value="36.7" lower_limit="23.2" upper_limit="50.2"/>
                    <measurement group_id="O3" value="57.1" lower_limit="43.3" upper_limit="71.0"/>
                    <measurement group_id="O4" value="50.0" lower_limit="36.1" upper_limit="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>30.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.5</ci_lower_limit>
            <ci_upper_limit>45.7</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>51.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>35.6</ci_lower_limit>
            <ci_upper_limit>66.4</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>43.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>28.5</ci_lower_limit>
            <ci_upper_limit>59.3</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1</title>
        <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
        <time_frame>Baseline and Week 1</time_frame>
        <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 1 or for whom ACR data were missing at Week 1 were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 7.5 mg</title>
            <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1</title>
          <description>Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:
≥ 20% improvement in 68-tender joint count;
≥ 20% improvement in 66-swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Health Assessment Questionnaire - Disability Index (HAQ-DI)
High-sensitivity C-reactive protein (hsCRP).</description>
          <population>Full analysis set; participants who prematurely discontinued from study drug prior to Week 1 or for whom ACR data were missing at Week 1 were considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="0.5" upper_limit="15.8"/>
                    <measurement group_id="O2" value="30.6" lower_limit="17.7" upper_limit="43.5"/>
                    <measurement group_id="O3" value="24.5" lower_limit="12.4" upper_limit="36.5"/>
                    <measurement group_id="O4" value="34.0" lower_limit="20.9" upper_limit="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>22.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.4</ci_lower_limit>
            <ci_upper_limit>37.5</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>16.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.1</ci_lower_limit>
            <ci_upper_limit>30.6</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusted for stratification factor prior bDMARD use.</method_desc>
            <param_type>Response Rate Difference</param_type>
            <param_value>25.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.6</ci_lower_limit>
            <ci_upper_limit>41.0</ci_upper_limit>
            <estimate_desc>Response Rate Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) at Week 12</title>
        <description>The FACIT Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better quality of life. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 7.5 mg</title>
            <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) at Week 12</title>
          <description>The FACIT Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better quality of life. A positive change from Baseline indicates improvement.</description>
          <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" lower_limit="-0.35" upper_limit="3.97"/>
                    <measurement group_id="O2" value="4.47" lower_limit="2.38" upper_limit="6.55"/>
                    <measurement group_id="O3" value="3.60" lower_limit="1.53" upper_limit="5.68"/>
                    <measurement group_id="O4" value="2.66" lower_limit="0.48" upper_limit="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.040</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>5.20</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.169</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>4.35</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.516</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.73</ci_lower_limit>
            <ci_upper_limit>3.43</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rheumatoid Arthritis Work Instability Scale (RA-WIS) at Week 12</title>
        <description>RA-WIS is a simple validated tool to evaluate work instability (the consequence of a mismatch between an individual's functional ability and their work tasks). RA-WIS consists of 23 questions relating to the participant's functioning in their work environment, each answered as Yes or No. The total score is the number of questions answered Yes, and ranges from 0 to 23.
A score &lt; 10 means low risk and no action is needed, scores between 10 and 17 indicate medium risk and appropriate advice and information should be given. If the score is &gt; 17, it means high risk and it could warrant referral.
A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants who were working and with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 7.5 mg</title>
            <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rheumatoid Arthritis Work Instability Scale (RA-WIS) at Week 12</title>
          <description>RA-WIS is a simple validated tool to evaluate work instability (the consequence of a mismatch between an individual's functional ability and their work tasks). RA-WIS consists of 23 questions relating to the participant's functioning in their work environment, each answered as Yes or No. The total score is the number of questions answered Yes, and ranges from 0 to 23.
A score &lt; 10 means low risk and no action is needed, scores between 10 and 17 indicate medium risk and appropriate advice and information should be given. If the score is &gt; 17, it means high risk and it could warrant referral.
A negative change from Baseline indicates improvement.</description>
          <population>Full analysis set participants who were working and with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
          <units>scores on a scale</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" lower_limit="-2.58" upper_limit="1.21"/>
                    <measurement group_id="O2" value="-3.22" lower_limit="-5.09" upper_limit="-1.36"/>
                    <measurement group_id="O3" value="-2.74" lower_limit="-4.75" upper_limit="-0.74"/>
                    <measurement group_id="O4" value="-2.24" lower_limit="-4.40" upper_limit="-0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.68</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.080</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.36</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.220</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.06</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Severity of Morning Stiffness at Week 12</title>
        <description>Morning stiffness severity was determined by the Patient's Assessment of Severity and Duration of Morning Stiffness questionnaire. Participants rated the severity of morning stiffness on awakening over the past 7 days on a scale from 0 (No morning stiffness) to 10 (Worst possible morning stiffness).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants randomized to receive placebo once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O2">
            <title>Upadacitinib 7.5 mg</title>
            <description>Participants randomized to receive upadacitinib 7.5 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O3">
            <title>Upadacitinib 15 mg</title>
            <description>Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1.</description>
          </group>
          <group group_id="O4">
            <title>Upadacitinib 30 mg</title>
            <description>Participants randomized to receive upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Severity of Morning Stiffness at Week 12</title>
          <description>Morning stiffness severity was determined by the Patient's Assessment of Severity and Duration of Morning Stiffness questionnaire. Participants rated the severity of morning stiffness on awakening over the past 7 days on a scale from 0 (No morning stiffness) to 10 (Worst possible morning stiffness).</description>
          <population>Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases to Week 12 was used.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" lower_limit="-1.65" upper_limit="-0.39"/>
                    <measurement group_id="O2" value="-2.83" lower_limit="-3.44" upper_limit="-2.22"/>
                    <measurement group_id="O3" value="-2.84" lower_limit="-3.45" upper_limit="-2.23"/>
                    <measurement group_id="O4" value="-2.98" lower_limit="-3.62" upper_limit="-2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.57</ci_lower_limit>
            <ci_upper_limit>-1.04</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.59</ci_lower_limit>
            <ci_upper_limit>-1.05</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Effect Model Repeat Measurement</method>
            <method_desc>MMRM model with fixed effects of treatment, visit and treatment-by-visit interaction, prior bDMARD use, and baseline value as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.73</ci_lower_limit>
            <ci_upper_limit>-1.18</ci_upper_limit>
            <estimate_desc>Difference = Upadacitinib - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Period 1: Weeks 1 to 12; Period 2: Weeks 12 to 60</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Period 1: Placebo</title>
          <description>Participants received placebo once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="E2">
          <title>Period 1: Upadacitinib 7.5 mg</title>
          <description>Participants received upadacitinib 7.5 mg once daily for 12 weeks in Period 1</description>
        </group>
        <group group_id="E3">
          <title>Period 1: Upadacitinib 15 mg</title>
          <description>Participants received upadacitinib 15 mg once daily for 12 weeks in Period 1</description>
        </group>
        <group group_id="E4">
          <title>Period 1: Upadacitinib 30 mg</title>
          <description>Participants received upadacitinib 30 mg once daily for 12 weeks in Period 1.</description>
        </group>
        <group group_id="E5">
          <title>Period 1+2: Upadacitinib 7.5 mg</title>
          <description>Participants originally randomized to upadacitinib 7.5 mg received upadacitinib 7.5 mg once daily for 12 weeks in Period 1 and up to Week 60 in Period 2. Participants originally randomized to placebo received upadacitinib 7.5 mg from Week 12 to Week 60.</description>
        </group>
        <group group_id="E6">
          <title>Period 1+2: Upadacitinib 15 mg</title>
          <description>Participants originally randomized to upadacitinib 15 mg received upadacitinib 15 mg once daily for 12 weeks in Period 1 and up to Week 60 in Period 2. Participants originally randomized to placebo received upadacitinib 15 mg from Week 12 to Week 60.</description>
        </group>
        <group group_id="E7">
          <title>Period 1+2: Upadacitinib 30 mg</title>
          <description>Participants originally randomized to upadacitinib 30 mg received upadacitinib 30 mg once daily for 12 weeks in Period 1 and up to Week 60 in Period 2. Participants originally randomized to placebo received upadacitinib 30 mg from Week 12 to Week 60.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Philadelphia chromosome positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Epiglottic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="55" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="60" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="8" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="17" subjects_affected="13" subjects_at_risk="65"/>
                <counts group_id="E6" events="8" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" events="7" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" events="8" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E5" events="71" subjects_affected="35" subjects_at_risk="65"/>
                <counts group_id="E6" events="59" subjects_affected="35" subjects_at_risk="64"/>
                <counts group_id="E7" events="64" subjects_affected="29" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E7" events="11" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" events="8" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" events="8" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="6" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E7" events="10" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

